1. Home
  2. MEIP vs SANW Comparison

MEIP vs SANW Comparison

Compare MEIP & SANW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • SANW
  • Stock Information
  • Founded
  • MEIP 2000
  • SANW 1980
  • Country
  • MEIP United States
  • SANW United States
  • Employees
  • MEIP N/A
  • SANW N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • SANW Farming/Seeds/Milling
  • Sector
  • MEIP Health Care
  • SANW Consumer Staples
  • Exchange
  • MEIP Nasdaq
  • SANW Nasdaq
  • Market Cap
  • MEIP 13.3M
  • SANW 11.6M
  • IPO Year
  • MEIP 2003
  • SANW 2010
  • Fundamental
  • Price
  • MEIP $2.18
  • SANW $5.48
  • Analyst Decision
  • MEIP Hold
  • SANW Strong Buy
  • Analyst Count
  • MEIP 1
  • SANW 1
  • Target Price
  • MEIP N/A
  • SANW $25.00
  • AVG Volume (30 Days)
  • MEIP 6.4K
  • SANW 6.3K
  • Earning Date
  • MEIP 05-13-2025
  • SANW 05-15-2025
  • Dividend Yield
  • MEIP N/A
  • SANW N/A
  • EPS Growth
  • MEIP N/A
  • SANW N/A
  • EPS
  • MEIP N/A
  • SANW N/A
  • Revenue
  • MEIP N/A
  • SANW $54,993,808.00
  • Revenue This Year
  • MEIP N/A
  • SANW N/A
  • Revenue Next Year
  • MEIP N/A
  • SANW $14.25
  • P/E Ratio
  • MEIP N/A
  • SANW N/A
  • Revenue Growth
  • MEIP 33.76
  • SANW 6.91
  • 52 Week Low
  • MEIP $1.46
  • SANW $2.10
  • 52 Week High
  • MEIP $4.10
  • SANW $11.60
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 53.30
  • SANW 49.38
  • Support Level
  • MEIP $2.05
  • SANW $5.36
  • Resistance Level
  • MEIP $2.25
  • SANW $5.88
  • Average True Range (ATR)
  • MEIP 0.11
  • SANW 0.35
  • MACD
  • MEIP 0.00
  • SANW 0.04
  • Stochastic Oscillator
  • MEIP 69.91
  • SANW 57.02

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About SANW S&W Seed Company (NV)

S&W Seed Co is a multi-crop, middle-market agricultural company. It is engaged in the breeding, production, and sale of alfalfa seed and sorghum seed. It also has a growing commercial market presence in sunflower and maintains an active stevia development program. The company's seed platform develops and supplies germplasm designed to produce higher yields for farmers globally. Its geographical segments include the United States, Australia, Saudi Arabia, Mexico, South Africa, and other countries. Maximum of revenue is earned from USA following Australia second and Mexico third.

Share on Social Networks: